Inhibitors of NO-synthases
The substances of the invention are highly effective low-molecular NO-synthases inhibitors. They can be synthesised easily and inexpensively in high purity via standard methods and exhibit selectivity for the bNOS present in the central nervous system which is involved in neuronal diseases as Alzheimer’s and Parkinson’s disease, multiple sclerosis and migraine. Thus, it is of particular importance that the inhibitors, after oral up-take and subsequent resorption via the intestinal epithelium, are able to cross the blood-brain barrier.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Humans vs Machines—Who’s Better at Recognizing Speech?
Are humans or machines better at recognizing speech? A new study shows that in noisy conditions, current automatic speech recognition (ASR) systems achieve remarkable accuracy and sometimes even surpass human…
Not Lost in Translation: AI Increases Sign Language Recognition Accuracy
Additional data can help differentiate subtle gestures, hand positions, facial expressions The Complexity of Sign Languages Sign languages have been developed by nations around the world to fit the local…
Breaking the Ice: Glacier Melting Alters Arctic Fjord Ecosystems
The regions of the Arctic are particularly vulnerable to climate change. However, there is a lack of comprehensive scientific information about the environmental changes there. Researchers from the Helmholtz Center…